In conclusion, targeted therapies including BRAF inhibitors and immune checkpoint inhibitors have become an important backbone in the treatment of melanoma BM and the on-going clinical trials will further redefine the clinical practice in this particular patient cohort. Here, BRAF is linked to melanoma.